Amyotrophic lateral sclerosis and spinocerebellar ataxia 2
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Amyotrophic lateral sclerosis (ALS) is usually sporadic, but 5%–10% of patients have a hereditary form of the disease. About 20% of familial patients have mutations in the SOD1 gene,1 and recently other gene mutations have been found in familial ALS: TDP-43, FUS, and VCP.2,–,5 Interestingly, the protein products of 2 of these genes, TDP-43 and FUS, are likely involved in RNA metabolism. TDP-43 forms cytoplasmic inclusions in neurons of patients with both sporadic and familial ALS and frontotemporal dementia.
Genetic risk factors may play a role in sporadic as well as familial ALS, but the results of association studies have been mixed. For example, the gene for the neurotrophic factor VEGF is a possible risk factor in various European populations,6 but studies in other populations did not confirm the finding.7 It is now clear that there is no genetic risk factor for ALS as strong as APOE is for Alzheimer disease, and finding and confirming weaker risk factors requires large studies in multiple populations with well-matched controls.
Several months ago, Elden and colleagues8 reported a novel risk factor for ALS in ATXN2, the gene for the polyglutamine expansion neurodegenerative disease spinocerebellar ataxia 2 (SCA2). This gene showed up in a screen for modifiers of TDP-43 toxicity in yeast and has a similar effect in Drosophila.8 TDP-43 and …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. David Beversdorf and Dr. Ryan Townley
► Watch
Related Articles
Topics Discussed
Alert Me
Recommended articles
-
Articles
Expanded ATXN2 CAG repeat size in ALS identifies genetic overlap between ALS and SCA2P. Van Damme, J.H. Veldink, M. van Blitterswijk et al.Neurology, May 11, 2011 -
Article
Ataxin-1 and ataxin-2 intermediate-length PolyQ expansions in amyotrophic lateral sclerosisFrancesca L. Conforti, Rossella Spataro, William Sproviero et al.Neurology, November 28, 2012 -
Articles
Evaluating the prevalence of polyglutamine repeat expansions in amyotrophic lateral sclerosisT. Lee, Y.R. Li, A. Chesi et al.Neurology, May 11, 2011 -
Article
Contribution of ATXN2 intermediary polyQ expansions in a spectrum of neurodegenerative disordersSerena Lattante, Stéphanie Millecamps, Giovanni Stevanin et al.Neurology, August 06, 2014